Prostate Surgeries and Interventions
Defines UnitedHealthcare coverage stance and medical necessity criteria for a range of prostate procedures (e.g., transurethral ablation, cryoablation, prostatic urethral lift, water vapor thermotherapy, water jet ablation and other listed interventions) for members covered under the payer's plans.
Removed coverage criteria for transperineal placement of biodegradable material.
Revised coverage criteria for prostatic urethral lift to allow 'lateral, with or without median lobe hyperplasia' (men ≥45 years) instead of earlier wording.
Changed transurethral water‑jet ablation language to state it is unproven and not medically necessary for malignant prostate tissue and other indications not listed as proven due to insufficient evidence.
Revised prostate artery embolization (PAE) coverage language to specify it is proven and medically necessary for individuals with BPH who are ineligible for other procedures due to factors such as prostate size or anesthesia risk.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.